Mimic human complexity in a beat!

OUR MISSION

At BiomimX® we develop clinically relevant and fast responsive technology driven solutions tailored made to fit applications in Big Diseases.

Integrating 3D cell culture and mechanical stimulation, BiomimX® proposes the next generation of beating organs-on-chips, allowing to recapitulate human organs’ function and human diseased states with an unprecedented level of precision.

OUR VISION

BiomimX® is a technology driven company projected towards the development of innovative and 3R compliant preclinical solutions that will revolutionize the standards for testing drug and medical devices.

Fully in line with our mission, BiomimX® is developing several models of human organs and diseases applicable to our main business lines.

Check out our pipeline!

Organs_website_weel_home__complete

Our Technology

Our innovative technology combines mechanical stimulation and 3D architecture with the advantages of the microscaled systems.

Explore

Our Products

uBeat® Platform to culture, uCase to organize, uBox to stimulate.

Explore

Our Services

Drug cardiotoxicity, Drug and Medical Device efficacy and much more. Towards personalized medicine applications.

Explore
Explore
Explore
Explore

Meet us

If you are curious and you want to deepen the potential of uBeat® Technology, the versatility of our products and the clinical relevance of our services, come talk to us at the Bio-Europe 2021, on March 22 - 25.
We'll be there!

BUSINESS AREAS

drug-safety-and-efficacy

DRUG DISCOVERY AND SAFETY

BiomimX® provides advanced human in vitro models to detect drug efficacy and adverse effects, representing a more clinically relevant alternative to existing models.

medical-device-assessment

MEDICAL DEVICE ASSESSMENT

In line with the new EU Medical Device Regulation (MDR (EU)2017/745), BiomimX® offers advanced preclinical models to test medical device efficacy before undergoing clinical trials.

precision-medicine-biomimx

PRECISION MEDICINE

Future developments include envisioned precision medicine approaches, where candidate compounds and therapies are screened on disease- and, ultimately, patient-specific models.

February 9, 2021
We are glad to announce that our latest study “Micro-electrode channel guide (µECG) technology: an online method for continuous electrical recording in a human beating heart-on-chip” is now on-line on Biofabrication. In this paper we present a new device capable of monitoring the electrical activity of beating cardiac microtissues, together with a proof-of-concept pharmacological validation. This work is the result of a great collaboration between Academia (Politecnico di Milano) and Industries (BiomimX® Srl & Accelera Srl).
Read it
January 21, 2021
2020 has taught us how crucial is to invest in Research, mostly to reduce technical time for testing drugs and medical devices. Paola Occhetta, BiomimX® CEO, and Marco Rasponi, BiomimX® President, explained on STARTUPPER (channel 821 Sky) episode, how our startup contributes to bring pharmaceutical companies to the market with more efficient therapies in a shorter time, thanks to our innovative technologies. If you missed it, you can watch it by clicking the button below.
Watch it!
January 20, 2021
Within the SINERGIA framework professor Paul Bourgine was the first speaker of our webinars series, invited by BiomimX® Srl. Prof. Bourgine’s laboratory targets the development of miniaturized human bone organs (hOssicles) in mice to be used as advanced model of healthy and malignant human hematopoiesis. This talk first covered how embryonic processes can be harnessed for the engineering of hOssicles. The advantages of the hOssicle approach as opposed to standard in vitro and in vivo models was also been discussed. For more info about our SINERGIA network:
Click Here
Previous
Next